Page 88 - Read Online

Page 130 De Mattia et al. Cancer Drug Resist 2019;2:116-30 I http://dx.doi.org/10.20517/cdr.2019.04

cancer patients treated with neo-adjuvant chemo-radiotherapy. Pharmacogenomics J 2011;11:214-26.
61. Libra M, Navolanic PM, Talamini R, Cecchin E, Sartor F, et al. Thymidylate synthetase mRNA levels are increased in liver metastases
of colorectal cancer patients resistant to fluoropyrimidine-based chemotherapy. BMC Cancer 2004;4:11.
62. Cecchin E, Perrone G, Nobili S, Polesel J, De Mattia E, et al. MTHFR-1298 A>C (rs1801131) is a predictor of survival in two
cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin.
Pharmacogenomics J 2015;15:219-25.
63. Pellicer M, García-González X, García MI, Robles L, Grávalos C, et al. Identification of new SNPs associated with severe toxicity to
capecitabine. Pharmacol Res 2017;120:133-7.
64. Ose J, Botma A, Balavarca Y, Buck K, Scherer D, et al. Pathway analysis of genetic variants in folate-mediated one-carbon metabolism-
related genes and survival in a prospectively followed cohort of colorectal cancer patients. Cancer Med 2018; doi: 10.1002/cam4.1407.
65. Ichikawa W, Takahashi T, Suto K, Sasaki Y, Hirayama R. Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in
patients treated with bolus 5-fluorouracil regimen. Clin Cancer Res 2006;12:3928-34.
66. Tsunoda A, Nakao K, Watanabe M, Matsui N, Ooyama A, et al. Associations of various gene polymorphisms with toxicity in colorectal
cancer patients receiving oral uracil and tegafur plus leucovorin: a prospective study. Ann Oncol 2011;22:355-61.
67. Gusella M, Bertolaso L, Bolzonella C, Pasini F, Padrini R. Frequency of uridine monophosphate synthase Gly(213)Ala polymorphism
in Caucasian gastrointestinal cancer patients and healthy subjects, investigated by means of new, rapid genotyping assays. Genet Test
Mol Biomarkers 2011;15:691-5.
68. Jennings BA, Loke YK, Skinner J, Keane M, Chu GS, et al. Evaluating predictive pharmacogenetic signatures of adverse events in
colorectal cancer patients treated with fluoropyrimidines. PLoS One 2013;8:e78053.
69. Loganayagam A, Arenas Hernandez M, Corrigan A, Fairbanks L, Lewis CM, et al. Pharmacogenetic variants in the DPYD, TYMS,
CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity. Br J Cancer 2013;108:2505-15.
70. Caronia D, Martin M, Sastre J, de la Torre J, García-Sáenz JA, et al. A polymorphism in the cytidine deaminase promoter predicts
severe capecitabine-induced hand-foot syndrome. Clin Cancer Res 2011;17:2006-13.
71. Dahan L, Ciccolini J, Evrard A, Mbatchi L, Tibbitts J, et al. Sudden death related to toxicity in a patient on capecitabine and irinotecan
plus bevacizumab intake: pharmacogenetic implications. J Clin Oncol 2012;30:e41-44.
72. Lévi F, Karaboué A, Saffroy R, Desterke C, Boige V, et al. Pharmacogenetic determinants of outcomes on triplet hepatic artery
infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228). Br J Cancer
2017;117:965-73.
73. Yap YS, Kwok LL, Syn N, Chay WY, Chia JWK, et al. Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-
induced hand-foot syndrome: a randomized clinical trial. JAMA Oncol 2017;3:1538-45.
74. De Mattia E, Cecchin E, Montico M, Labriet A, Guillemette C, et al. Association of STAT-3 rs1053004 and VDR rs11574077 With
FOLFIRI-related gastrointestinal toxicity in metastatic colorectal cancer patients. Front Pharmacol 2018;9:367.
75. Garziera M, Virdone S, De Mattia E, Scarabel L, Cecchin E, et al. HLA-G 3’UTR polymorphisms predict drug-induced G3-4
toxicity related to folinic acid/5-fluorouracil/oxaliplatin (FOLFOX4) chemotherapy in non-metastatic colorectal cancer. Int J Mol Sci
2017;18;E1366.
76. Garziera M, Bidoli E, Cecchin E, Mini E, Nobili S, et al. HLA-G 3’UTR polymorphisms impact the prognosis of stage II-III CRC
patients in fluoropyrimidine-based treatment. PLoS One 2015;10:e0144000.
77. De Mattia E, Dreussi E, Montico M, Gagno S, Zanusso C, et al. A clinical-genetic score to identify surgically resected colorectal cancer
patients benefiting from an adjuvant fluoropyrimidine-based therapy. Front Pharmacol 2018;9:1101.
78. Re VD, Caggiari L, Zorzi MD, Talamini R, Racanelli V, et al. Genetic diversity of the KIR/HLA system and outcome of patients with
metastatic colorectal cancer treated with chemotherapy. PLoS One 2014;9:e84940.
79. Abad A, Martínez-Balibrea E, Viéitez JM, Alonso-Orduña V, García Alfonso P, et al. Genotype-based selection of treatment of patients
with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial. Ann Oncol 2018;29:439-44.
80. McLeod HL, Sargent DJ, Marsh S, Green EM, King CR, et al. Pharmacogenetic predictors of adverse events and response to
chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol
2010;28:3227-33.
81. Toffoli G, Cecchin E, Gasparini G, D’Andrea M, Azzarello G, et al. Genotype-driven phase I study of irinotecan administered in
combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 2010;28:866-71.
82. Di Francia R, Frigeri F, Berretta M, Cecchin E, Orlando C, et al. Decision criteria for rational selection of homogeneous genotyping
platforms for pharmacogenomics testing in clinical diagnostics. Clin Chem Lab Med 2010;48:447-59.
83. Afzal S, Gusella M, Vainer B, Vogel UB, Andersen JT, et al. Combinations of polymorphisms in genes involved in the 5-Fluorouracil
metabolism pathway are associated with gastrointestinal toxicity in chemotherapy-treated colorectal cancer patients. Clin Cancer Res
2011;17:3822-9.
84. Kozyra M, Ingelman-Sundberg M, Lauschke VM. Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear
receptors can be important determinants of interindividual differences in drug response. Genet Med 2017;19:20-9.